Business Description
Compugen Ltd
ISIN : IL0010852080
Total Employee Number:
75Description
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 46.03 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.1 | |||||
Interest Coverage | 1087.62 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.91 | |||||
Beneish M-Score | -1.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 107.6 | |||||
3-Year Book Growth Rate | 6.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.63 | |||||
9-Day RSI | 56.55 | |||||
14-Day RSI | 56.38 | |||||
3-1 Month Momentum % | -29.54 | |||||
6-1 Month Momentum % | -10.16 | |||||
12-1 Month Momentum % | 13.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.23 | |||||
Quick Ratio | 6.23 | |||||
Cash Ratio | 6.12 | |||||
Days Payable | 102.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.06 | |||||
Operating Margin % | 42.26 | |||||
Net Margin % | 47.97 | |||||
EBITDA Margin % | 42.26 | |||||
FCF Margin % | 43.12 | |||||
OCF Margin % | 43.54 | |||||
ROE % | 49.9 | |||||
ROA % | 28.01 | |||||
ROIC % | 145.08 | |||||
3-Year ROIIC % | 590.46 | |||||
ROC (Joel Greenblatt) % | 907.91 | |||||
ROCE % | 29.76 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.41 | |||||
Forward PE Ratio | 38 | |||||
PE Ratio without NRI | 6.41 | |||||
PS Ratio | 3.14 | |||||
PB Ratio | 2.36 | |||||
Price-to-Tangible-Book | 2.36 | |||||
Price-to-Free-Cash-Flow | 7.11 | |||||
Price-to-Operating-Cash-Flow | 7.06 | |||||
EV-to-EBIT | 3.01 | |||||
EV-to-EBITDA | 3.01 | |||||
EV-to-Revenue | 1.27 | |||||
EV-to-Forward-Revenue | 15.53 | |||||
EV-to-FCF | 2.96 | |||||
Price-to-Graham-Number | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 2.6 | |||||
| Price-to-Net-Cash | 2.67 | |||||
Earnings Yield (Greenblatt) % | 33.22 | |||||
FCF Yield % | 13.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Compugen Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₪) | 221.974 | ||
| EPS (TTM) (₪) | 1.131 | ||
| Beta | 1.9719 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 1.44 | ||
| Volatility % | 66.47 | ||
| 14-Day RSI | 56.38 | ||
| 14-Day ATR (₪) | 0.314071 | ||
| 20-Day SMA (₪) | 6.98965 | ||
| 12-1 Month Momentum % | 13.18 | ||
| 52-Week Range (₪) | 4.35 - 9.24 | ||
| Shares Outstanding (Mil) | 94.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Compugen Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Compugen Ltd Stock Events
| Event | Date | Price (₪) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:30 | In 108 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 107 days | ||
| General meeting for 2026 | 2026-09-16 18:00 | In 53 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-03 08:30 | In 9 days | ||
| Second quarter earnings results for 2026 | 2026-08-03 | In 8 days | ||
| Jones Trading Fireside Chat Series | 2026-06-15 10:30 | 5.81 (-0.94%) | ||
| Guidance call for 2026 | 2026-05-19 10:00 | 7.96 (-9.50%) | ||
| First quarter earnings conference call for 2026 | 2026-05-18 08:30 | 8.79 (+2.15%) | ||
| First quarter earnings results for 2026 | 2026-05-18 | 8.79 (+2.15%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 08:45 | 7.45 (-0.92%) |
Show
Entries
Compugen Ltd Frequently Asked Questions
What is Compugen Ltd(XTAE:CGEN)'s stock price today?
The current price of XTAE:CGEN is ₪7.25. The 52 week high of XTAE:CGEN is ₪9.24 and 52 week low is ₪4.35.
When is next earnings date of Compugen Ltd(XTAE:CGEN)?
The next earnings date of Compugen Ltd(XTAE:CGEN) is 2026-08-03.
Does Compugen Ltd(XTAE:CGEN) pay dividends? If so, how much?
Compugen Ltd(XTAE:CGEN) does not pay dividend.
Press Release
Articles on Compugen Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers